Development of Severe Hypophosphatemia from Acquired Fanconi Syndrome during Treatment with Abiraterone

Volume 3 | Issue 1 Development of Severe Hypophosphatemia from Acquired Fanconi Syndrome during Treatment with Abiraterone Chamberlain ED1, Vanek C2, Alumkal JJ3 and Graff JN*3,4 1Department of Medicine, Oregon Health & Science University, Portland, OR 2Division of Endocrinology, Oregon Health & Science University, Portland, OR 3Knight Cancer Institute, Oregon Health & Science University, Portland, OR 4Portland VA Medical Center, Portland, OR *Corresponding author: Graff JN, 3710 SW US Veterans Hospital Road, MC P3CHEMO, Portland, OR 97239, Tel: 503-220-8262 x 55688, Fax: 503-494-6197, E-mail: graffj@ohsu.edu Case Report Open Access


Introduction
A 77 year-old man presented with an initial diagnosis of metastatic prostate cancer to the bones in 2009.Medical castration with the luteinizing hormone releasing hormone (LHRH) agonist, leuprolide acetate, led to an initial decrease in prostate-specific antigen (PSA).Unfortunately, his disease progressed over the ensuing twelve months prompting initiation of concomitant antiandrogen therapy with bicalutamide followed by systemic therapy with docetaxel chemotherapy, which was discontinued after one cycle for significant anorexia and bleeding.His mCRPC was subsequently treated in September of 2011 with abiraterone (1000 mg orally daily) in combination with prednisone 5 mg orally twice a day.He began the intravenous bisphosphonate zoledronic acid in November 2011 for his bone metastases.His cancer responded well to abiraterone, demonstrated by an interval decrease in PSA from 540 ng/ml (September 2011) to 19 ng/ml (January 2012).However, this response was not durable, marked by a rise in PSA to 111 ng/ml (July 2012).
While considering clinical trial participation, routine lab work demonstrated a critically low serum phosphorous of 0.6 mg/dl (range 2.5-4.5 mg/dl).This abnormality was discovered during ongoing treatment with abiraterone (September 2012), a full year after initiation.Neither his referring oncologist nor primary care provider had checked the phosphorous either prior to or during treatment with abiraterone.Endocrinology evaluated the patient for his critical hypophosphatemia.The patient reported persistent chronic knee pain but was otherwise asymptomatic.The differential included vitamin D deficiency, gastrointestinal malabsorption, oncogenic osteomalacia, exposure to zoledronic acid, and renal phosphorous wasting from hyperparathyroidism or a renal tubule defect from an acquired Fanconi syndrome.The patient had normal vitamin D (25-OH) levels, lack of clinical findings suggestive of malabsorption, normal PTH, a new findings of high urine glucose of 500 mg/dl (normal range 0-15) in the setting of normal non-fasting serum glucose of 113 mg/dl (normal <140) and 2+ glycine on qualitative amino acid urine screen (Table 1).A normal SPEP ruled out light chain deposition disease as a cause for acquired Fanconi syndrome.Comparison of phosphate and creatinine in the serum and urine revealed a decreased ratio of renal tubular maximum reabsoroption rate of phosphate to the glomerular filtration rate (TmP/GFR) [3].This established inappropriate urinary loss of phosphate due to a proximal renal tubule defect.This, together with his normoglycemic glucosuria and aminoaciduria, highly suggests the diagnosis of acquired Fanconi syndrome.Of note, his medication list lacked drugs well-known to cause acquired Fanconi syndrome.He discontinued abiraterone treatment and initiated potassium-phosphate supplementation as well as calcitriol to aid intestinal phosphorous absorption.His zoledronic acid was also discontinued out of concern it could be exacerbating the hypophosphatemia.Repeat lab work demonstrated an improved serum phosphorus level of 1.6 mg/dl, though persistent glucosuria.Six months after the diagnosis of Fanconi syndrome, he declined further follow-up for both his acquired Fanconi syndrome and metastatic prostate cancer.

Case 1
A 74 year-old man was diagnosed with Gleason 4+3 adenocarcinoma of the prostate and was treated with external beam radiation therapy in 2008.In 2012, he was found to have metastatic cancer to the bones and began treatment with leuprolide and bicalutamide.He also started denosumab for his bone metastases, which he received for 12 months.His cancer progressed, and in October 2013, he started abiraterone (1000 mg orally daily) with prednisone 5 mg orally twice a day.At the same time, his denosumab was changed to zoledronic acid when he changed medical systems.

Case 2
When he began abiraterone acetate with prednisone, he had a baseline phosphorous of 2.2 mg/dl.Within one month of beginning abiraterone and prednisone, his phosphorous fell to 1.6 mg/dl and 0.9 mg/dl at four months.Work up of his hypophosphatemia revealed a normal 25-hydroxy vitamin D level, lack of clinical findings for malabsorption and a mild elevation in PTH (76 pg/ml).His serum and urine studies revealed a decreased TmP/GFR consistent with inappropriate renal excretion of phosphorus (Table 1).Aminoaciduria and normoglycemic glucosuria were also present and are not features of hyperparathyroidism.The patient was diagnosed with abiratrone induced acquired Fanconi syndrome.
He continued on abiraterone because he had continued clinical response.Phosphorus supplementation was initiated in the form of sodium phosphorous/potassium phosphorous (Neutra-Phos) 250 mg twice a day.However, his severe hypophosphatemia required oral doses of 1500 mg per day, plus potassium phosphorous 500 mg twice a week intravenously.He was hospitalized for a cardiac event and received potassium phosphorous 1500 mg per day intravenously for six consecutive days.This raised his serum phosphorous to 2.0 mg/dl.He also began to take calcitriol 0.25 mg orally per day.Despite the efforts to raise his phosphorous, his risk of profound hypophosphatemia leading to life-threatening cardiac dysrhythmias in setting of his underlying cardiac disease that included coronary artery disease status post bypass grafting was felt to outweigh the benefit of abiratrone.Abiraterone was discontinued.Four weeks later, in the setting of continued oral and intravenous supplemental phosphorous repletion, calcitriol and zoledronic acid, his phosphorous rose to 1.9 mg/dl.
Here we report two cases of hypophosphatemia resulting from acquired Fanconi syndrome during treatment with abiraterone acetate for mCRPC.Each patient demonstrated classical features of Fanconi syndrome: a disease of renal dysfunction of reduced proximal tubule reabsorption threshold causing hypophosphatemia, normoglycemic glucosuria, and aminoaciduria.
Fanconi syndrome is associated with a wide variety of both inherited and acquired conditions.This disease was first described in 1924 and better defined in 1936 by Guido Fanconi, for whom the disease is named, who evaluated children presenting with rickets, growth retardation, and glucosuria.Although the underlying pathology has not been clearly elucidated, experimental models using a compound, maleic acid, showed renal tubule dysfunction characterized by defective luminal entry of the compound, excessive back leak, or interference with Na, K, -ATPase activity [9].Known drug offenders leading to acquired Fanconi syndrome include drugs from antibacterial [10], antiviral [11], antiretroviral [12,13] and anticonvulsant classes [14].Known associations within the anticancer drug classes include ifosfamide, cisplatin, carboplatin, streptozocin, azacitidine, suramin, and mercaptopurine [5].Abiraterone acetate has yet to be included on this list.These patients were on zoledronic acid, and this agent was linked to Fanconi syndrome in two previously published case reports [15,16].Another key differential etiology to consider includes the rare paraneoplastic syndrome called oncogenic osteomalacia, characterized by renal phosphate wasting and severe hypophosphatemia leading to osteomalacia.It is most often seen with mesenchymal tumors, though a literature review spanning thirty-four years  revealed 24 case reports of this syndrome in patients with metastatic prostate cancer [17].Two more cases have been reported since [18,19].Unfortunately, we do not have a baseline serum phosphorous level for the first patient, and he declined follow-up after discontinuing abiraterone.While we do not know exactly when the hypophosphatemia developed in the first patient, it could have developed long before it was discovered.Either bisphosphate therapy or a paraneoplastic syndrome leading to hypophosphatemia is possible.However, the second patient had a near normal baseline serum phosphorous before treatment despite having widely metastatic disease which makes a paraneoplastic syndrome less likely.He developed severe hypophosphatemia while taking both abiraterone and zoledronic acid.However, his phosphorous began to resolve after stopping the abiraterone despite continued therapy with zoledronic acid.This supports the argument that abiraterone alone led to this patient's hypophosphatemia.

Discussion
In the two phase III clinical trials of abiraterone with prednisone versus placebo with prednisone, hypophosphatemia was seen more commonly in the abiraterone treated groups [2,3].Any grade of hypophosphatemia occurred in 23.8% on the abiraterone arm versus 15.7% on the placebo arm [5].Significant hypophosphatemia (serum phosphorous < 2 mg/dl) was seen in 7.2% on abiraterone versus 5.8% on placebo.There are no reports from these studies of aminoaciduria or glycosuria in the setting of normal serum glucose.Although the differential for hypophosphatemia is broad and includes vitamin D deficiency, nutritional deficiency, hyperparathyroidism, oncogenic osteomalacia, or concurrent bisphosphonate therapy, it is unclear what caused it in the clinical trials, though we retrospectively propose abiraterone induced acquired Fanconi syndrome as a potential mechanism for this observed abnormality.
Drug induced Fanconi syndrome is usually reversible by discontinuing the offending agent and initiating vitamin and mineral supplementation to make up for urinary losses.However, despite initiating these interventions, permanent renal damage may occur and long term sequelae may be severe with the spectrum of renal disease ranging from subclinical and biochemical evidence of renal damage to irreversible damage and bone disease (osteomalacia) from urinary excretion of phosphate.Prognosis of druginduced Fanconi syndrome varies according to the offending medication.Reversal of Fanconi syndrome caused by outdated tetracyclines, for example, may take up to one year [20].Whereas valproic acid induced Fanconi syndrome usually improves promptly with discontinuation of the medication [14].
We can expect continued wide use of abiraterone acetate for patients with mCRPC, and it is clear that careful monitoring of electrolytes such as potassium and liver function tests is necessary.Our case reports demonstrate that hypophosphatemia due to acquired Fanconi syndrome is another important side effect of treatment with abiraterone.We propose that patients treated with this medication undergo regular laboratory testing including serum phosphorus levels.By regularly monitoring patients for early signs of disease with these simple laboratory evaluations, Fanconi syndrome can be detected early and potential irreversible damage may be prevented.
Submit your next manuscript to Annex Publishers and benefit from: Submit your manuscript at http://www.annexpublishers.com/paper-submission.php→ Easy online submission process → Rapid peer review process → Open access: articles available free online → Online article availability soon after acceptance for Publication → Better discount on subsequent article submission → More accessibility of the articles to the readers/researchers within the field